Основная статистика
| CIK | 1764013 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immunovant, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 3, 2025 |
Exhibit 99.1 Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients •First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients •Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyro |
|
| September 3, 2025 |
exhibit992 Targeted science, Tailored solutions for people with autoimmune disease Batoclimab Graves’ Disease Proof-of-Concept Study Remission Data September 2025 Exhibit 99. |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| August 11, 2025 |
Exhibit 10.5 IMMUNOVANT, INC. 2019 EQUITY INCENTIVE PLAN CAPPED VALUE APPRECIATION RIGHT AWARD GRANT NOTICE Participant: [NAME] (the “Participant”) Company: Immunovant, Inc., a Delaware corporation (the “Company”) Plan: Immunovant, Inc. 2019 Equity Incentive Plan (as amended, the “Plan”) Notice: The Participant has been granted an award of Capped Value Appreciation Rights (“CVARs”) in accordance w |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact nam |
|
| August 11, 2025 |
Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 •Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025 •All other clinical trials in previously announced six-indications remain on track with increas |
|
| August 11, 2025 |
Separation Agreement and General Release with Renee Barnett, dated as of May 9, 2025 Exhibit 10.2 April 20, 2025 Modified May 9, 2025 Renee Barnett [***] RE: Separation Agreement and General Release Dear Renee, Your employment with IMVT Corporation will be terminated effective April 20, 2025 (the “Separation Date”). This Separation Agreement and General Release (this “Agreement”) sets forth the terms and conditions under which IMVT Corporation is offering you additional pay and be |
|
| August 11, 2025 |
Employment Agreement with Eric Venker, dated as of July 28, 2025. Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of July 28, 2025, by and between Eric Venker (the “Executive”) and IMVT Corporation (the “Company”). Reference is made to that certain Amended and Restated Executive Employment Agreement entered into by and between the Executive and Roivant Sciences, Inc. (“RSI”), an affiliate of the Company, dated as |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Com |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 29, 2025 |
Immunovant, Inc. Insider Trading Pol Exhibit 19.1 IMMUNOVANT, INC. AMENDED AND RESTATED INSIDER TRADING POLICY 1.Introduction This Insider Trading Policy (the “Policy”) determines acceptable transactions in the securities of certain publicly-traded companies by the directors, officers and employees of Immunovant, Inc. and its consolidated subsidiaries (collectively, “Immunovant”). This Policy is meant to supplement and be read in con |
|
| May 29, 2025 |
Employment Agreement with Tiago Girao, dated as of April 21, 2025. Exhibit 10.19 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of April 21, 2025, by and between Tiago Girao (the “Executive”) and IMVT Corporation (the “Company”). RECITALS A.The Company desires the association and services of the Executive and the Executive’s skills, abilities, background and knowledge, and is willing to engage the Executive’s services on the |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38906 |
|
| May 29, 2025 |
EX-99.1 2 exhibit9912025529.htm EX-99.1 Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 •Immunovant’s new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves’ disease (GD) and a potentially reg |
|
| May 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Comm |
|
| May 29, 2025 |
Separation Agreement and General Release with Peter Salzmann, dated as of April 20, 2025. Exhibit 10.25 April 20, 2025 Peter Salzmann [***] RE: Separation Agreement and General Release Dear Pete, Your employment with Immunovant, Inc. will be terminated effective April 20, 2025 (the “Separation Date”). This Separation Agreement and General Release (this “Agreement”) sets forth the terms and conditions under which Immunovant, Inc. is offering you additional pay and benefits in exchange f |
|
| April 30, 2025 |
Calculation of Filing Fee Tables S-8 Immunovant, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock Other 6,804,463 $ 14.805 $ 100,740,074.72 0.0001531 $ 15,423.31 Total Offering Amounts: $ 100,740,074.7 |
|
| April 30, 2025 |
As filed with the U.S. Securities and Exchange Commission on April 30, 2025 As filed with the U.S. Securities and Exchange Commission on April 30, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware (State of incorporation or organization) 83-2771572 (I.R.S. Employer Identification |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Co |
|
| April 21, 2025 |
exhibit992 Immunovant Corporate Update April 21, 2025 Exhibit 99.2 2 Forward-Looking Statements Roivant Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fac |
|
| April 21, 2025 |
Exhibit 99.1 Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 •Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant •Pete Salzmann, M.D. retired from his role as Im |
|
| March 19, 2025 |
EX-99.2 3 exhibit992.htm EX-99.2 Targeted science, Tailored solutions for people with autoimmune disease MG & CIDP Results March 2025 Exhibit 99.2 Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," |
|
| March 19, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Co |
|
| March 19, 2025 |
Exhibit 99.1 Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies •Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm ( |
|
| February 6, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of November 27, 2024, by and between Christopher Van Tuyl (the “Executive”) and IMVT Corporation (the “Company”). RECITALS A.The Company desires the association and services of the Executive and the Executive’s skills, abilities, background and knowledge, and is willing to engage the Executive’s servi |
|
| February 6, 2025 |
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 Exhibit 99.1 Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 •Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves’ disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinjector •Additional results from batoclimab proof-of-concept study in GD, i |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| January 24, 2025 |
Up to 5,654,990 Shares of Common Stock Offered by Selling Stockholders Filed Pursuant to Rule 424(b)(3) Registration No. 333-275419 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 9, 2023) Up to 5,654,990 Shares of Common Stock Offered by Selling Stockholders The selling stockholders named in this prospectus supplement or their permitted pledgees, assignees, donees, transferees or their respective successors-in-interest, referred to collectively as the selling st |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| January 24, 2025 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) Immunovant, Inc. |
|
| January 15, 2025 |
Exhibit 7.01 Schedule A Covered Persons Roivant has a board of directors (such members of the board of directors collectively, the "Covered Persons"). The name, present principal occupation and country of citizenship of each of the Covered Persons is set forth below, along with the principal business address of the employer of each of the Covered Persons. Name Principal Business Address of Employe |
|
| January 14, 2025 |
Targeted science, Tailored solutions for people with autoimmune disease 2025 J.P. Morgan Healthcare Conference January 14, 2025 Exhibit 99.1 Forward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “ma |
|
| January 14, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| January 13, 2025 |
Exhibit 10.2 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 13, 2025 is entered into by and among Immunovant, Inc., a |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| January 13, 2025 |
Immunovant Announces $450 Million Private Placement Exhibit 99.1 Immunovant Announces $450 Million Private Placement NEW YORK, January 13, 2025 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it has agreed to sell an aggregate of 22,500,000 shares of common stock at a purchase price of $20.00 per share to three institutional accredite |
|
| January 13, 2025 |
Share Purchase Agreement, by and between the Company and the Purchasers, dated January 13, 2025. Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this “Agreement”) is dated as of January 13, 2025, by and among Immunovant, Inc., a Delaware corporation (t |
|
| November 7, 2024 |
Exhibit 99.1 Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 •Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402 •Proof of concept data from batoclimab trial in Graves’ disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibi |
|
| November 7, 2024 |
Immunovant Development Update November 7, 2024 Exhibit 99.2 Forward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design, |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| November 7, 2024 |
a, dated as of November 5, 2024. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of November 5, 2024, by and between Melanie Gloria (the “Executive”) and IMVT Corporation (the “Company”). RECITALS A. The Company desires the association and services of the Executive and the Executive’s skills, abilities, background and knowledge, and is willing to engage the Executive’s services on |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exac |
|
| September 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| September 9, 2024 |
Targeted science, Tailored solutions for people with autoimmune disease Graves’ Disease Program Update September 9, 2024 Exhibit 99. |
|
| September 9, 2024 |
Immunovant Provides Update on Graves’ Disease Development Program EX-99.1 2 exhibit99120240909.htm EX-99.1 Exhibit 99.1 Immunovant Provides Update on Graves’ Disease Development Program •High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12 •High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on ATDs at week 12 •Strong correlation observed between degree of IgG lowering and c |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| August 6, 2024 |
Exhibit 99.1 Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 •Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025) •Progressed development of lead asset IMVT-1402 with 3 Investigational New Dr |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact nam |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Co |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 29, 2024 |
Immunovant Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 IMMUNOVANT, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Board of Directors (the “Board”) of Immunovant, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incenti |
|
| May 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Comm |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38906 IMMUNOVANT, INC. (Exact name of r |
|
| May 29, 2024 |
Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 •Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March |
|
| April 15, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 15, 2024 As filed with the U.S. Securities and Exchange Commission on April 15, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 83-2771572 (State of incorporation or organization) (I.R.S. Employer Identificati |
|
| April 15, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Immunovant, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share Other 5,823,319 (3) $29.655(2) $172,6 |
|
| February 14, 2024 |
IMVT / Immunovant, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-imvt123123a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immunovant, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45258J102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 13, 2024 |
February 13, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| February 12, 2024 |
Exhibit 99.1 Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 •Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year •Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two fiscal years •Initial period 1 data from Phase 2b clinical trial of batoclimab in |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact |
|
| February 12, 2024 |
Employment Agreement with Michael Geffner, dated as of January 9, 2024. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of January 9, 2024, by and between Michael Geffner, MD, MBA (the “Executive”) and IMVT Corporation (the “Company”). RECITALS A. The Company desires the association and services of the Executive and the Executive’s skills, abilities, background and knowledge, and is willing to engage the Executive’s se |
|
| January 9, 2024 |
exhibit991 Targeted science, Tailored solutions for people with autoimmune disease 42nd Annual J. |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| December 20, 2023 |
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease Exhibit 99.1 Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease NEW YORK, December 20, 2023 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in pat |
|
| November 28, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| November 28, 2023 |
Targeted science, Tailored solutions for people with autoimmune disease Portfolio Update November 28, 2023 Exhibit 99. |
|
| November 28, 2023 |
Exhibit 99.1 Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential •Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 •IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 study •IMVT-1402 600 mg was observed to d |
|
| November 9, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 IMMUNOVANT, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF IMMUNOVANT, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between IMMUNOVANT, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exac |
|
| November 9, 2023 |
Exhibit 4.3 Immunovant, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 Section 2. |
|
| November 9, 2023 |
Exhibit 99.1 Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023 •Positive initial Phase 1 data for IMVT-1402 announced, bolstering best-in-class potential •Initial 600 mg multiple-ascending dose (MAD) cohort data for IMVT-1402 expected in November 2023 •Initial Phase 2 proof-of-concept data for batoclimab in Graves’ disease expected by end |
|
| November 9, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 IMMUNOVANT, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF IMMUNOVANT, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between IMMUNOVANT, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] a |
|
| November 9, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 IMMUNOVANT, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF IMMUNOVANT, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between IMMUNOVANT, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws |
|
| November 9, 2023 |
Sales Agreement, by and between the Registrant and Leerink Partners LLC, dated November 9, 2023. Exhibit 1.2 Execution Version IMMUNOVANT, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT November 9, 2023 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Immunovant, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Iss |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 9, 2023 Registration No. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| November 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunovant, Inc. |
|
| October 4, 2023 |
IMVT / Immunovant Inc / Roivant Sciences Ltd. - SC 13D/A Activist Investment SC 13D/A 1 ef20011983sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7)* Under the Securities Exchange Act of 1934 Immunovant, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45258J 102 (CUSIP Number) 7th Floor 50 Broadway London SW1H 0DB United Kingdom +44 207 400 3347 With copie |
|
| September 29, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251865 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED JANUARY 14, 2021) 7,370,000 Shares Common Stock We are offering 7,370,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol “IMVT.” On September 27, 2023, the last reported sale price of our common stock on Na |
|
| September 28, 2023 |
Free Writing Prospectus pursuant to Rule 433 dated September 27, 2023 FWP Free Writing Prospectus pursuant to Rule 433 dated September 27, 2023 Registration Statement No. |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| September 28, 2023 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this “Agreement”), dated as of September 26, 2023, by and between ROIVANT SCIENCES LTD. (the “Investor”), a Bermuda exempted limited company, and IMMUNOVANT, INC. (the “Company”), a Delaware corporation. The Investor and the Company are collectively referred to as the “Parties.” WHEREAS, the Company inte |
|
| September 28, 2023 |
EX-1.1 Exhibit 1.1 Execution Version Immunovant, Inc. (a Delaware corporation) 7,370,000 Shares of Common Stock UNDERWRITING AGREEMENT September 27, 2023 Leerink Partners LLC Piper Sandler & Co. Guggenheim Securities, LLC Wells Fargo Securities, LLC As Representatives of the several Underwriters c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Piper Sandler & Co |
|
| September 27, 2023 |
Free Writing Prospectus pursuant to Rule 433 dated September 26, 2023 Free Writing Prospectus pursuant to Rule 433 dated September 26, 2023 Registration Statement No. |
|
| September 26, 2023 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 26, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251865 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanyin |
|
| September 26, 2023 |
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results Exhibit 99.1 Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results •IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab •No decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks |
|
| September 26, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| September 26, 2023 |
Targeted science, Tailored solutions for people with autoimmune disease IMVT-1402 Initial First-in-human Data Presentation September 26, 2023 Exhibit 99. |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| August 10, 2023 |
Exhibit 99.1 Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023 •Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023 (single-ascending dose) and October/November 2023 (multiple-ascending dose) •Phase 2 proof-of-concept data for batoclimab in Graves’ disease (GD) expected in the fourth quarter of 2023 •Global cli |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact nam |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38906 IMMUNOVANT, INC. (Exact name of R |
|
| May 22, 2023 |
Employment Agreement with Jay Stout, dated as of April 11, 2023. Exhibit 10.24 Employment Agreement This Employment Agreement (this “Agreement”) is entered into as of April 11, 2023, by and between Jay Stewart Stout (the “Executive”) and IMVT Corporation (the “Company”). Recitals A.The Company desires the association and services of the Executive and the Executive’s skills, abilities, background and knowledge, and is willing to engage the Executive’s services o |
|
| May 22, 2023 |
Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023 •Investigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectively •Phase 1 clinical trial in healthy subjects initiated in New Zealand •Phase 2 proof-of-concept clinical trial of batocl |
|
| May 22, 2023 |
exhibit992 IMVT-1402 Update May 22, 2023 Exhibit 99.2 Forward-looking Statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design,” “pla |
|
| May 22, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Comm |
|
| April 5, 2023 |
Power of Attorney (included on the signature page of this Form S-8). S-8 As filed with the U.S. Securities and Exchange Commission on April 5, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 83-2771572 (State of incorporation or organization) (I.R.S. Employer Identificati |
|
| April 5, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Immunovant, Inc. |
|
| March 27, 2023 |
exhibit991 Targeted Science, Tailored Solutions Corporate Presentation March 2023 Exhibit 99. |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 14, 2023 |
IMVT / Immunovant Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| February 3, 2023 |
Form of Restricted Stock Unit Grant Notice and Agreement for the UK Sub-Plan Exhibit 10.3 Non-U.S. Immunovant, Inc. Restricted Stock Unit Grant Notice – Non-U.S. (2019 Equity Incentive Plan) Immunovant, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to |
|
| February 3, 2023 |
As filed with the Securities and Exchange Commission on February 3, 2023 S-8 1 d419313ds8.htm S-8 As filed with the Securities and Exchange Commission on February 3, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 83-2771572 (State or other jurisdiction of incorporation or or |
|
| February 3, 2023 |
Form of Stock Option Grant Notice and Option Agreement for the Immunovant, Inc. 2023 Inducement Plan Exhibit 10.5 Immunovant, Inc. Stock Option Grant Notice (2023 Inducement Plan) Immunovant, Inc. (the “Company”), pursuant to its 2023 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in the Option Agreement, the |
|
| February 3, 2023 |
Immunovant, Inc. 2023 Inducement Plan Exhibit 10.4 Immunovant, Inc. 2023 Inducement Plan Adopted by the Board of Directors: February 1, 2023 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A |
|
| February 3, 2023 |
Calculation of Filing Fee Table. EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Immunovant, Inc. |
|
| February 3, 2023 |
Exhibit 10.6 Immunovant, Inc. Restricted Stock Unit Grant Notice (2023 Inducement Plan) Immunovant, Inc. (the “Company”), pursuant to its 2023 Inducement Plan (the “Plan”), hereby awards to the individual whose name is set forth below (“Participant”) a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Aw |
|
| February 3, 2023 |
Form of Stock Option Grant Notice and Agreement for the UK Sub-Plan Exhibit 10.2 Non-U.S. Immunovant, inc. Stock Option Grant Notice – Non-U.S. (2019 Equity Incentive Plan) Immunovant, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notic |
|
| February 3, 2023 |
UK Sub-Plan to the Immunovant, Inc. 2019 Equity Incentive Plan Exhibit 10.1 UK SUB-PLAN TO THE IMMUNOVANT, INC. 2019 EQUITY INCENTIVE PLAN This sub-plan (the "UK Sub-Plan") to the Immunovant, Inc. 2019 Equity Incentive Plan (the “Plan”) governs the grant of Stock Awards to United Kingdom Employees, and has been adopted in accordance with Section 2(b)(x) of the Plan. The UK Sub-Plan incorporates all the provisions of the Plan except as modified in accordance w |
|
| February 3, 2023 |
Exhibit 99.1 Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022 •A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023 •A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in chronic inflammatory demyelinating polyneuropathy (CIDP) were initiated, as expected |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| January 9, 2023 |
EX-99.1 2 exhibit991.htm EX-99.1 Corporate Presentation January 2023 Exhibit 99.1 Forward-looking Statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” “should,” “expect,” “believe, |
|
| December 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| December 8, 2022 |
LifeSci Capital Fireside Chat December 8, 2022 Exhibit 99.1 Forward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," ?may,? ?might,? ?will,? ?would,? ?should,? ?expect,? ?believe,? ?estimate,? ?design, |
|
| December 5, 2022 |
IMVT / Immunovant Inc / RTW INVESTMENTS, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Immunovant, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45258J102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| December 2, 2022 |
IMVT / Immunovant Inc / RTW INVESTMENTS, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Immunovant, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45258J102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exac |
|
| November 4, 2022 |
Exhibit 99.1 Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022 •IMVT-1402, a next generation, subcutaneously administered, neonatal fragment crystallizable receptor (FcRn) inhibitor unveiled •New development programs for batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease announced •Phase 3 trials of bat |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| October 5, 2022 |
12,500,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251865 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED JANUARY 14, 2021) 12,500,000 Shares Common Stock We are offering 12,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol ?IMVT.? On October 3, 2022, the last reported sale price of our common stock on Nas |
|
| October 4, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| October 4, 2022 |
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock Exhibit 99.1 Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock New York, October 4, 2022 (GLOBE NEWSWIRE) – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offerin |
|
| October 4, 2022 |
Underwriting Agreement, among the Company and SVB Securities LLC, dated as of October 3, 2022. Exhibit 1.1 Execution Version Immunovant, Inc. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENT October 3, 2022 SVB Securities LLC As Representative of the several Underwriters c/o SVB Securities LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Immunovant, Inc., a Delaware corporation (the “Company”), confirms its agreement with SVB |
|
| September 28, 2022 |
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn Exhibit 99.1 Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn ?In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. ?Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023. ?Previously announced programs for lead asset batoclimab continue at full speed. |
|
| September 28, 2022 |
CONFIDENTIAL Building a Leading Franchise Next Generation FcRn: IMVT-1402 September 2022 For Investor Audiences Only Exhibit 99. |
|
| September 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| September 7, 2022 |
Immunovant Announces Plans to Study Batoclimab in Two New Indications Committed to enabling normal lives for people with autoimmune disease September 7, 2022 EExhibit 99. |
|
| September 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| September 7, 2022 |
Immunovant Announces Two New Development Programs for Batoclimab Exhibit 99.2 Immunovant Announces Two New Development Programs for Batoclimab ?Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first half of 2024 ?Plan to initiate a Phase 2 trial in Graves? Disease in early 2023 with initial results expected in the second |
|
| August 19, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact nam |
|
| August 5, 2022 |
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022 Exhibit 99.1 Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022 NEW YORK, August 05, 2022 (GLOBE NEWSWIRE) ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal first quarter ended |
|
| August 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Co |
|
| June 30, 2022 |
DEF 14A 1 imvt-20220331defproxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| June 30, 2022 |
DEFA14A 1 defa14acoverpage-3x31x22.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the |
|
| June 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 IMMUNOVANT, INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(1) Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(4) Equity Common Stock, $0.0001 par value per share Other(2) 4,659,315(3) $4.24(2) $19 |
|
| June 8, 2022 |
As filed with the U.S. Securities and Exchange Commission on June 8, 2022 As filed with the U.S. Securities and Exchange Commission on June 8, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 83-2771572 (State of incorporation or organization) (I.R.S. Employer Identification No |
|
| June 8, 2022 |
Phase 3 Development for Batoclimab in Thyroid Eye Disease Investor Presentation June 8, 2022 Exhibit 99. |
|
| June 8, 2022 |
Exhibit 99.1 Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 ?Immunovant plans to initiate two placebo-controlled Phase 3 clinical trials of batoclimab in thyroid eye disease (TED) in the second half of calendar year 2022 with top-line data expe |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38906 IMMUNOVANT, INC. (Exact name of R |
|
| June 8, 2022 |
Exhibit 21.1 Immunovant, Inc. List of Subsidiaries Subsidiary Jurisdiction Immunovant Treasury Inc. Delaware Immunovant Sciences Ltd. Bermuda Immunovant Sciences Holdings Limited United Kingdom IMVT Corporation Delaware Immunovant Sciences GmbH Switzerland |
|
| June 8, 2022 |
Employment Agreement with Mark Levine, dated as of January 19, 2022. EXHIBIT 10.16 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into as of January 19, 2022, by and between Mark S. Levine (the ?Executive?) and IMVT Corporation (the ?Company?). RECITALS A.The Company desires the association and services of the Executive and the Executive?s skills, abilities, background and knowledge, and is willing to engage the Executive?s services on |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Comm |
|
| March 30, 2022 |
Immunovant R&D Day Enabling normal lives for people with autoimmune disease March 30, 2022 Exhibit 99. |
|
| March 30, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 11, 2022 |
IMVT / Immunovant Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact |
|
| February 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| February 4, 2022 |
Exhibit 10.2 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY ***) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and IMMUNOVANT SCIENCES GMBH TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. RELATED AGREEMENTS AND EXHIBITS |
|
| February 4, 2022 |
Exhibit 99.1 Immunovant Reports Financial Results for the Quarter Ended December 31, 2021 Company Ended the Quarter With Cash of Approximately $527.0 Million NEW YORK, February 4, 2022 (GLOBE NEWSWIRE) ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal fi |
|
| February 4, 2022 |
Employment Agreement with William Macias, dated as of October 25, 2021, as amended. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into as of October 25, 2021, as amended, by and between William Macias, M.D. Ph.D. (the ?Executive?) and IMVT Corporation (the ?Company?). RECITALS A.The Company and Executive previously entered into a Master Consulting Agreement, dated as of April 13, 2021 (the ?Consulting Agreement?). B.The Company desires |
|
| February 4, 2022 |
Exhibit 10.3 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY ***) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. SAMSUNG BIOLOGICS CO., LTD. PRODUCT SERVICE AGREEMENT ? COMMERCIAL PRODUCT DRUG SUBSTANCE This Product Service Agreement (this ?PSA?) is made effective as of the dat |
|
| January 10, 2022 |
As filed with the U.S. Securities and Exchange Commission on January 10, 2022 As filed with the U.S. Securities and Exchange Commission on January 10, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware (State of incorporation or organization) 83-2771572 (I.R.S. Employer Identificatio |
|
| January 7, 2022 |
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference Exhibit 99.1 Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference NEW YORK, Jan. 7, 2022 ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the 40th Annual J.P. Morgan Healthcar |
|
| January 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| January 5, 2022 |
Phase 3 Development for Batoclimab in Myasthenia Gravis Corporate Update January 2022 eExhibit 99. |
|
| December 30, 2021 |
Exhibit 99.1 Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 NEW YORK, December 30, 2021 (GLOBE NEWSWIRE) ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced that the Company achieved alignment with the F |
|
| December 30, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| November 23, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| November 17, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| November 17, 2021 |
Stifel 2021 Virtual Healthcare Conference Investor Presentation November 17, 2021 For Investor Audiences Only Exhibit 99. |
|
| November 17, 2021 |
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference Exhibit 99.1 Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference NEW YORK, Nov. 12, 2021 ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Confe |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exac |
|
| November 5, 2021 |
Exhibit 99.1 Immunovant Reports Financial Results for the Quarter Ended September 30, 2021 Company Ended the Quarter With Cash of Approximately $559 Million NEW YORK, November 5, 2021 (GLOBE NEWSWIRE) ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal fir |
|
| November 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| September 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| September 27, 2021 |
Immunovant to Participate in Roivant R&D Day 2021 Exhibit 99.1 Immunovant to Participate in Roivant R&D Day 2021 NEW YORK, Sept. 27, 2021 ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat during Roivant R&D Day 2021 on Tuesday, September 28, 2021 at |
|
| September 27, 2021 |
EX-99.2 3 roivantpipelineday2021.htm EX-99.2 For Investor Audiences Only Roivant R&D Day Investor Presentation September 28, 2021 Exhibit 99.2 For Investor Audiences Only Forward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The u |
|
| September 15, 2021 |
Employment Agreement with Renee Barnett, dated as of September 14, 2021. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into as of September 14, 2021, by and between Renee Barnett (the ?Executive?) and IMVT Corporation (the ?Company?). RECITALS A. The Company desires the association and services of the Executive and the Executive?s skills, abilities, background and knowledge, and is willing to engage the Executive?s services o |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| September 15, 2021 |
Myasthenia Gravis Patient Insights Investor Presentation September 2021 EExhibit 99. |
|
| September 15, 2021 |
Immunovant Appoints Renee Barnett as Chief Financial Officer Exhibit 99.1 Immunovant Appoints Renee Barnett as Chief Financial Officer ?Ms. Barnett brings a wealth of financial experience to Immunovant ?Expands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, September 15, 2021 ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people w |
|
| August 12, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte |
|
| August 9, 2021 |
Exhibit 99.1 Immunovant Reports Financial Results for the Quarter Ended June 30, 2021 Company Ended the Quarter With Cash of Approximately $379 Million and Subsequently Received a Direct Investment of $200 Million from Roivant NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoi |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact nam |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Co |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Co |
|
| August 2, 2021 |
IMVT / Immunovant Inc / Roivant Sciences Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 6)* Under the Securities Exchange Act of 1934 Immunovant, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45258J 102 (CUSIP Number) Suite 1, 3rd Floor, 11-12 St. James?s Square, London SW1Y 4LB, United Kingdom +44 207 400 3347 With copies to: Derek J. D |
|
| August 2, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte |
|
| August 2, 2021 |
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences Exhibit 99.1 Immunovant Receives $200 Million Strategic Investment from Roivant Sciences ?Proceeds will fund continued development of IMVT-1401 in multiple indications NEW YORK, August 02, 2021 (GLOBE NEWSWIRE) ? Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has received a $2 |
|
| August 2, 2021 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this ?Agreement?), dated as of August 2, 2021, by and between ROIVANT SCIENCES LTD. (the ?Investor?), a Bermuda exempted limited company, and IMMUNOVANT, INC. (the ?Company?), a Delaware corporation. The Investor and the Company are collectively referred to as the ?Parties.? WHEREAS, the Investor wishes to purchase from the Compa |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Comm |
|
| July 13, 2021 |
Consulting Agreement between Immunovant, Inc. and Pamela Yanchik Connealy, dated July Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this ?Agreement?) is made and entered into as of July 13, 2021 by and between Immunovant, Inc. (?Immunovant?) and Pamela Yanchik Connealy (?Consultant?). Immunovant and Consultant may be referred to herein individually as a ?Party? and collectively as the ?Parties.? W I T N E S S E T H: WHEREAS, Immunovant desires to engage Consultant to |
|
| June 1, 2021 |
Corporate Update Conference Call June 1, 2021 Exhibit 99.2 2 Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as ?may,? ?might,? ?will,? ?expect,? ?plan,? ?anticipate,? ?believe,? ?estimate,? ?intend,? ?fu |
|
| June 1, 2021 |
Employment Agreement with Rita Jain, dated as of December 23, Exhibit 10.17 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into as of December 23, 2020, by and between Rita Jain (the ?Executive?) and IMVT Corporation (the ?Company?). RECITALS A.The Company desires the association and services of the Executive and the Executive?s skills, abilities, background and knowledge, and is willing to engage the Executive?s services on the |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38906 IMMUNOVANT, INC. (Exact name of R |
|
| June 1, 2021 |
Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021 ?Immunovant plans to resume clinical development of IMVT-1401 in Myasthenia Gravis (MG) and Warm Autoimmune Hemolytic Anemia (WAIHA) as well as initiate two additional mid-to-late stage studies in the next year ?Program-wide data review suggests that IMVT-1401 has a |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (Comm |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5)* Under the Securities Exchange Act of 1934 Immunovant, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45258J 102 (CUSIP Number) Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom +44 207 400 3347 With copies to: Derek J. D |
|
| February 17, 2021 |
February 17, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| February 16, 2021 |
Separation Agreement and General Release, dated November 13, 2020, by and between W. Bradford Exhibit 10.1 October 23, 2020 (revised November 5, 2020) Brad Middlekauff [***] RE: Separation Agreement and General Release Dear Brad, Your employment with IMVT Corporation (?Immunovant?) will be terminated effective November 6, 2020 (the ?Separation Date?). This Separation Agreement and General Release (this ?Agreement?) sets forth the terms and conditions under which IMVT Corporation is offerin |
|
| February 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact |
|
| February 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 16, 2021 |
Exhibit 99.1 Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020 Company Ended the Quarter With Cash of Approximately $422 Million NEW YORK, Feb. 16, 2021 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal third |
|
| February 2, 2021 |
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 Exhibit 99.1 Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 NEW YORK, Feb. 2, 2021 – Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401. The Company has become aware of a physiological signal consis |
|
| February 2, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) ( |
|
| January 15, 2021 |
988,448 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(7) Registration No. 333-251865 988,448 Shares of Common Stock The selling stockholders named in this prospectus or their permitted transferees, referred to collectively as the selling stockholders, may offer and sell from time to time up to 988,448 shares of our common stock, par value $0.0001 per share. The selling stockholders may offer, sell or distribut |
|
| January 15, 2021 |
Up to $150,000,000 Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. 333-251865 Up to $150,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with SVB Leerink LLC, or SVB Leerink, relating to the sale of shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of common stock having an aggrega |
|
| January 12, 2021 |
January 12, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Margaret Schwartz Re: Immunovant, Inc. Registration Statement on Form S-3 File No. 333-251865 Acceleration Request Requested Date: January 14, 2021 Requested Time: 5:00 P.M. Eastern Standard Time Ladies and Gentlemen: In accordance with Rule 461 under t |
|
| January 4, 2021 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 IMMUNOVANT, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF IMMUNOVANT, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between IMMUNOVANT, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws |
|
| January 4, 2021 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 IMMUNOVANT, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF IMMUNOVANT, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between IMMUNOVANT, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] a |
|
| January 4, 2021 |
Exhibit 4.3 Immunovant, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 7 Section |
|
| January 4, 2021 |
Sales Agreement, by and between the Registrant and SVB Leerink LLC, dated January 4, 2021. Exhibit 1.2 IMMUNOVANT, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT January 4, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Immunovant, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows: 1.Issuance and Sale of Shares. The |
|
| January 4, 2021 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 IMMUNOVANT, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF IMMUNOVANT, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [l], between Immunovant, Inc., a Delaware corporation (the “Company”), and [l], a [corporation] [national banking association] organized and existing under the laws |
|
| January 4, 2021 |
As filed with the Securities and Exchange Commission on January 4, 2021 Registration No. |
|
| November 12, 2020 |
11,389,969 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-235975 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated April 9, 2020) 11,389,969 Shares of Common Stock This prospectus supplement supplements the prospectus, dated April 9, 2020 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-235975). This prospectus supplement is being fil |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) |
|
| November 12, 2020 |
Exhibit 99.1 Immunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020 Company Ended the Quarter With Cash of Approximately $444 Million NEW YORK, November 12, 2020 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal se |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exac |
|
| September 18, 2020 |
Unregistered Sales of Equity Securities - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2020 Immunovant, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38906 83-2771572 (State or other jurisdiction (Commission File Number) (IRS Emp |
|
| September 18, 2020 |
IMVT / Immunovant, Inc. / Roivant Sciences Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4)* Under the Securities Exchange Act of 1934 Immunovant, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45258J 102 (CUSIP Number) Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom +44 207 400 3347 With copies to: Derek J. D |
|
| September 4, 2020 |
IMVT / Immunovant, Inc. / Roivant Sciences Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3)* Under the Securities Exchange Act of 1934 Immunovant, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45258J 102 (CUSIP Number) Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom +44 207 400 3347 With copies to: Derek J. D |
|
| September 3, 2020 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-248498 333-248540 PROSPECTUS 5,270,093 Shares Common Stock We are offering 5,270,093 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol “IMVT.” On September 1, 2020, the last reported sale price of our common stock on Nasdaq was $34.67 per share. Roivan |
|
| September 2, 2020 |
POS EX As filed with the U.S. Securities and Exchange Commission on September 1, 2020. Registration No. 333-248498 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 2836 83-2771572 (State or other j |
|
| September 1, 2020 |
S-1MEF As filed with the U.S. Securities and Exchange Commission on September 1, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 2836 83-2771572 (State or other jurisdiction of incorporation or organiza |
|
| August 31, 2020 |
Form S-1 Table of Contents As filed with the U.S. Securities and Exchange Commission on August 31, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 2836 83-2771572 (State or other jurisdiction of incorpo |
|
| August 31, 2020 |
CORRESP Via EDGAR Submission August 31, 2020 Securities and Exchange Commission 100 F Street, N. |
|
| August 31, 2020 |
Form of Underwriting Agreement. EX-1.1 2 d103112dex11.htm EX-1.1 Exhibit 1.1 Immunovant, Inc. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT September [●], 2020 SVB Leerink LLC Guggenheim Securities, LLC as Representatives of the several Underwriters c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 |
|
| August 31, 2020 |
IMMUNOVANT, INC. 320 West 37th Street New York, NY 10018 August 31, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Immunovant, Inc. Registration Statement on Form S-1 File No. 333-248498 Acceleration Request Requested Date: September 1, 2020 Requested Time: 4:00 p.m., Eastern Daylight Time |
|
| August 31, 2020 |
Employment Agreement with Michael Elliott, dated as of August 24, EX-10.17 Exhibit 10.17 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of August 24, 2020, by and between Michael Elliott (the “Executive”) and IMVT Corporation (the “Company”). RECITALS A. The Company desires the association and services of the Executive and the Executive’s skills, abilities, background and knowledge, and is willing to engage the Executive’s s |
|
| August 25, 2020 |
11,389,969 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-235975 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated April 9, 2020) 11,389,969 Shares of Common Stock This prospectus supplement supplements the prospectus, dated April 9, 2020 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-235975). This prospectus supplement is being filed to update |
|
| August 25, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2020 Immunovant, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation) (Commissi |
|
| August 25, 2020 |
EX-99.2 ASCEND MG Topline Results Conference Call August 25, 2020 Exhibit 99.2 Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “expect,” “plan,” “anticipate,” “believe,” “estima |
|
| August 25, 2020 |
EX-99.1 Exhibit 99.1 Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis Company to Host Conference Call on August 25, 2020 at 8:30am EDT • 3.8-point mean improvement on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale was |
|
| August 21, 2020 |
11,389,969 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-235975 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated April 9, 2020) 11,389,969 Shares of Common Stock This prospectus supplement supplements the prospectus, dated April 9, 2020 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-235975). This prospectus supplement is being filed to update |
|
| August 21, 2020 |
Submission of Matters to a Vote of Security Holders - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2020 Immunovant, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38906 83-2771572 (State or other jurisdiction (Commission File Number) (IRS Em |
|
| August 19, 2020 |
DRS Table of Contents Confidential Treatment Requested by Immunovant, Inc. Pursuant to 17 C.F.R. § 200.83 As confidentially submitted to the U.S. Securities and Exchange Commission on August 19, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registra |
|
| August 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact nam |
|
| August 12, 2020 |
Immunovant Reports Financial Results for the Quarter Ended June 30, 2020 Exhibit 99.1 Immunovant Reports Financial Results for the Quarter Ended June 30, 2020 NEW YORK, August 12, 2020 (GLOBE NEWSWIRE) – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal first quarter ended June 30, 2020. Immunovant ended the quarter with appr |
|
| August 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38906 83-2771572 (State or other jurisdiction of incorporation or organization) (C |
|
| August 12, 2020 |
11,389,969 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-235975 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated April 9, 2020) 11,389,969 Shares of Common Stock This prospectus supplement supplements the prospectus, dated April 9, 2020 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-235975). This prospectus supplement is being fil |
|
| July 9, 2020 |
our definitive proxy statement DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| July 9, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| June 30, 2020 |
S-8 As filed with the U.S. Securities and Exchange Commission on June 29, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 83-2771572 (State of incorporation or organization) (I.R.S. Employer Identificati |
|
| June 29, 2020 |
11,389,969 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
